<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
  <title>Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis - VetSRev</title>
  <link rel="stylesheet" href="/vendor/bootstrap-4.3.1.min.css">
  <link rel="stylesheet" href="/vendor/fontawesome-5.8.1.min.css">

  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Roboto:ital,wght@0,100;0,300;0,400;0,700;1,400&display=swap" rel="stylesheet">

  <link rel="stylesheet" href="/assets/style.css" media="screen" type="text/css">

  <link rel="apple-touch-icon" sizes="180x180" href="/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/favicon-16x16.png">
  <link rel="manifest" href="/site.webmanifest">
</head>

<body>
  <!-- HEADER -->
  <div class="header">
    <div class="container">
      <img src="/assets/CEVMLogo.png" alt="logo"/>
      <div class="title">
        <h1>VetSRev</h1>
        <p class="hidden-xs">Database of veterinary systematic reviews</p>
      </div>
    </div>
  </div>

  <!-- Navigation -->
  <div class="container">
    <nav class="navbar navbar-expand navbar-light bg-light">
      <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation">
        <span class="navbar-toggler-icon"></span>
      </button>

      <div class="collapse navbar-collapse" id="navbarSupportedContent">
        <ul class="navbar-nav mr-auto">
          <li class="nav-item"><a class="nav-link" href="/">Home</a></li>
          <li class="nav-item"><a class="nav-link" href="/about.html">About VetSRev</a></li>
        </ul>
      </div>
    </nav>
  </div>

  <!-- CONTENT -->
  <div class="container">
  <div class="publication">
  <h1>Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis</h1>
  <h2>Li, A. and Garcia, D. A. and Lyman, G. H. and Carrier, M.</h2>

  
  <p>Thromb Res (2019) 173: 158–163</p>
  

  
  <p>DOI: <a href="https://doi.org/10.1016/j.thromres.2018.02.144">10.1016/j.thromres.2018.02.144</a></p>
  

  
  <h2>Abstract</h2>
  <p>INTRODUCTION: It is unclear if direct oral anticoagulants (DOACs) are effective and safe alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer-associated venous thromboembolism (VTE). We aim to synthesize existing literature that compared DOACs versus LMWHs in this high-risk population. MATERIALS AND METHODS: We conducted a systematic review using EMBASE, MEDLINE and CENTRAL for all observational studies and randomized controlled trials (RCTs) (PROSPERO: CRD42017080898). Two authors independently reviewed study eligibility, extracted data, and assessed bias. Primary outcomes included 6-month recurrent VTE and major bleeding. Secondary outcomes included clinically relevant non-major bleeding (CRNMB) and mortality. RESULTS: We screened 426 articles, reviewed 25 in full-text, and selected 13 and 2 for qualitative and quantitative synthesis, respectively. Based on a meta-analysis of the 2 RCTs, DOACs had lower 6-month recurrent VTE (42/725) when compared to LMWH (64/727) (RR: 0.65 (0.42-1.01)). However, DOACs had higher major bleeding (40/725) when compared to LMWH (23/727) (RR 1.74 (1.05-2.88)). Similarly, CRNMB was higher (RR 2.31 (0.85-6.28)) for patients receiving DOACs. There was no difference in mortality (RR 1.03 (0.85-1.26)). Observational studies were heterogeneous with high risks of bias but showed recurrent VTE rates consistent with the meta-analysis. CONCLUSIONS: DOACs were more effective than LMWHs to prevent recurrent VTE but were associated with a significantly increased risk of major bleeding as well as a trend toward more CRNMB. The absolute risk differences were small (2-3%) for both primary outcomes and may reflect better compliance with DOACs than LMWHs.</p>
  

  <h2>Citation</h2>
  <p class="citation"><span id="li_direct_2019">Li, A., Garcia, D. A., Lyman, G. H., &amp; Carrier, M. (2019). Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. <i>Thromb Res</i>, <i>173</i>, 158–163. https://doi.org/10.1016/j.thromres.2018.02.144 <b>Humans, Administration, Oral, *Heparin, use, *Factor Xa inhibitors, *Low-molecular-weight, *Neoplasms, *Venous thrombosis, Anticoagulants/administration &amp; dosage/adverse effects/*therapeutic use, Hemorrhage/chemically induced, Heparin, Low-Molecular-Weight/administration &amp; dosage/adverse effects/*therapeutic, Neoplasms/*complications, Secondary Prevention, Thrombosis/*drug therapy/*etiology, Venous Thromboembolism/*drug therapy/*etiology</b></span> </p>


  <h2>Keywords</h2>
  <ul>
    
    
      <li>Humans</li>
    
      <li>Administration</li>
    
      <li>Oral</li>
    
      <li>*Heparin</li>
    
      <li>use</li>
    
      <li>*Factor Xa inhibitors</li>
    
      <li>*Low-molecular-weight</li>
    
      <li>*Neoplasms</li>
    
      <li>*Venous thrombosis</li>
    
      <li>Anticoagulants/administration & dosage/adverse effects/*therapeutic use</li>
    
      <li>Hemorrhage/chemically induced</li>
    
      <li>Heparin</li>
    
      <li>Low-Molecular-Weight/administration & dosage/adverse effects/*therapeutic</li>
    
      <li>Neoplasms/*complications</li>
    
      <li>Secondary Prevention</li>
    
      <li>Thrombosis/*drug therapy/*etiology</li>
    
      <li>Venous Thromboembolism/*drug therapy/*etiology</li>
    
  </ul>

</div>

  </div>

  <!-- FOOTER -->
  <div class="container">
    <div class="footer">


      <h3>VetSRev</h3>
      <p class="strap">Database of veterinary systematic reviews</p>

      <p>To cite this resource please use the following:</br>
      Veterinary Systematic Review database (2021) VetSRev database (Version 2.0). Available at: https://vetsrev.nottingham.ac.uk.</p>


      <p class="smallprint"><a href="/cookies.html">Cookies policy</a></p>

    </div>
  </div>

  <!-- Cookie-Alert -->
  <div class="alert alert-dark alert-dismissible cookiealert" role="alert">

    We'd like to set some analytics cookies to help us improve our website.

    <a href="/cookies/">Learn more.</a>
    <button type="button" class="btn btn-outline-secondary btn-sm declinecookies" data-dismiss="alert">Decline</button>
    <button type="button" class="btn btn-primary btn-sm acceptcookies">Accept</button>

    <button type="button" class="close" data-dismiss="alert" aria-label="Close">
      <span aria-hidden="true">&times;</span>
    </button>
  </div>


  <!-- jQuery first, then Popper.js, then Bootstrap JS -->
  <script src="/vendor/jquery-3.5.1.min.js"></script>
  <script src="/vendor/popper.min.js "></script>
  <script src="/vendor/bootstrap-4.3.1.min.js "></script>

  


  


  <!-- cookies and Google Analytics-->
  <script src="/assets/cookies.js "></script>

</body>
</html>
